Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 279 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis, Relapsing-Remitting Clear all
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

NCT03870763
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate, Peginterferon Beta-1a, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 11:11 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

NCT02833714
View directory record Official record
Conditions
RELAPSING REMITTING MULTIPLE SCLEROSIS
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 1 Interventional

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

NCT00645749
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Helminth ova
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Jul 21, 2026, 11:11 AM EDT
Withdrawn No phase listed Observational

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

NCT02419638
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Placebo, Ocrelizumab, Avonex
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

Treatment Interruption of Natalizumab

NCT01071083
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 4 Interventional Results available

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

NCT02255656
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
alemtuzumab GZ402673
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
52
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ofatumumab with PRF, ofatumumab with AI
Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jul 21, 2026, 11:11 AM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01144351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ELND002, Placebo
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
17
States / cities
Berkeley, California • Fresno, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 3 Interventional Results available

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
19 Years to 58 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Jul 21, 2026, 11:11 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

NCT01058005
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Jul 21, 2026, 11:11 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

NCT02038049
View directory record Official record
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
VAY736, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Long Beach, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

NCT00050778
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 50 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
31
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jul 21, 2026, 11:11 AM EDT
Withdrawn Not applicable Interventional

Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis

NCT05482542
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab
Other · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 58 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 1Phase 2 Interventional

Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

NCT00587691
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Tovaxin Autologous T Cell Vaccine
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Bellaire, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 21, 2026, 11:11 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

MS-ResearchBiomarkerS

NCT05204459
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2041
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 4 Interventional

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

NCT01591551
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab (Tysabri)
Drug
Lead sponsor
Cornerstone Health Care, PA
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Patchogue, New York • High Point, North Carolina • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

NCT01006265
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 21, 2026, 11:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
24
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Active, not recruiting Not applicable Interventional

Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis

NCT04009005
View directory record Official record
Conditions
Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis
Interventions
Therapeutic diet and lifestyle
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

NCT01185821
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BAF312
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 56 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
8
States / cities
Miami, Florida • Pompano Beach, Florida • Tallahassee, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Jul 21, 2026, 11:11 AM EDT
Completed No phase listed Observational

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

NCT01945359
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Jul 21, 2026, 11:11 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

NCT06408259
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ozanimod, Fingolimod, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
10 Years to 17 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
12
States / cities
Loma Linda, California • Sacramento, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Completed No phase listed Observational

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk

NCT02440126
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 21, 2026, 11:11 AM EDT